OpenAI is advancing longevity science through its latest AI model, which reportedly enhances cellular reprogramming by proposing modifications to Yamanaka factors in collaboration with Retro Bio. The model, referred to as GPT-4b, is designed to assist in drug discovery and the creation of proteins that can rejuvenate normal cells into stem cells. This initiative marks a significant step in the application of AI in scientific discovery, with implications for extending life expectancy. Notable organizations, including Google DeepMind and the Chan Zuckerberg Initiative, are also leveraging large language models to accelerate biomedical research, focusing on the cellular basis of health and disease.